



Call for participation: HPV DNA screening proficiency study 2022 (597)

External quality assessment for laboratories that perform **HPV screening**.

Testing for oncogenic HPV in cervical cancer screening is a globally recommended health policy. For HPV screening, it is important to detect the most carcinogenic viruses (HPV16 and 18) at high sensitivity, but for less carcinogenic viruses it is not important to determine the exact type. Complete HPV genotyping is particularly important for vaccinology, but as the HPV genotyping proficiency panel contains 44 challenge samples, many laboratories have asked for a smaller proficiency panel tailored to what is important for assessing the quality of HPV screening services.

Participant laboratories will be asked to perform HPV screening using one or more of their usual HPV screening assays on the 12 challenge samples in this panel. The panel will evaluate the detection of the major oncogenic HPV types as well as detection of other oncogenic HPV types in groups.

Composition of sample material

The panel consists of 12 samples containing purified whole genomic plasmids of **HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68a** and **68b** in a background of human cellular DNA. Each sample may contain either no HPV, a single HPV type or a mixture of HPV types at varying concentrations.

Participation fee

The price for one panel (12 samples as described above) is 330 Euros for commercial entities and 140 Euros for academic entities. Participants from low and lower middle-income countries (World Bank classification with GNI (gross national income) per capita: <4045 USD) can apply for waiving of fee. Laboratories that have outstanding payments from past Global HPV LabNet proficiency studies will need to clear their debts before their registration is accepted.

Data submission

The International HPV Reference Laboratory in Sweden is organizing this study in collaboration with the Swedish external quality assurance provider Equalis AB, who is responsible for management and distribution. Laboratories that have more than one assay are encouraged to provide results on each assay they commonly use. Data submitted will become the property of the organizers and may be analyzed for publication by the Global HPV LabNet either as an internal document or peer reviewed manuscript. All results will be handled in a coded anonymous fashion, with summaries grouped by method. The code linking data to originating laboratories will be kept confidential. Laboratories that provide data within the required time-frame will receive a copy of their own results and the summary data.

Scientific issues

Dr. Joakim Dillner
HPV International Reference Laboratory, Sweden
Center for Cervical Cancer Prevention
E-mail: joakim.dillner@ki.se or www.hpvcenter.se



Registration

Application forms for the 2022 study can be found at: equalis.se

Important

- If the delivery address is different from the participants address, for example if the shipment is sent to a local distributor, please enter the delivery address in the field "Other Comments" in the application form.
- If an import permit is required to send samples to you, please send it to us by e-mail to info@equalis.se

Preliminary dates

7th of June 2022: Registration for participation opens.

26th of August 2022: Registration for participation closes.

September/October 2022: Dispatch of panels begins.

Participation, management and practical issues

Equalis AB, Sweden www.equalis.se

E-mail: HPV@equalis.se